logo
logo

Inflammatix Announces Additional $12.1 Million Funding From Barda For Virabac Ez Acute Infection Test

Nov 18, 2021•over 3 years ago

Amount Raised

$12.1 Million

Burlingame

Description

Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funding is part of a BARDA contract worth up to $72 million if all options are exercised.

Company Information

Company

Inflammatix

Location

Burlingame, California, United States

About

Inflammatix is a molecular diagnostics company that is reimagining diagnostics by reading the patient’s immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company’s initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Each test will be developed to run on the company’s sample-to-answer isothermal instrument platform in under 30 minutes, enabling the power of precision medicine at the point of care. The Burlingame, California based company is funded by Khosla Ventures, Northpond Ventures, D1 Capital Partners, and Think.Health Ventures, among others. For more information, please visit www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc). This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C00034.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech